Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement

GoviEx Uranium Inc CEO Daniel Major talked with Proactive's Stephen Gunnion about the company’s latest milestone—the submission of a draft Environmental and Social Impact Assessment (ESIA) for its Muntanga uranium project in Zambia. This filing follows the completion of a feasibility study that defined the project’s structure and has triggered the next phase of regulatory review. “We now wait for ZEMA, the Zambian Environmental Management Agency, to come back with their comments,” Major said, expressing confidence in the clean design and minimal environmental issues identified so far. He added that the company hopes to receive approvals in the third or fourth quarter of this year, potentially allowing construction to commence, pending financing. Major also emphasised Muntanga’s strategic position as one of the few near-term uranium projects that could help address an anticipated supply deficit from 2029 onwards. Citing the latest Red Book report, he noted that while uranium resources are ample, there is a shortfall of ready-to-develop projects. He also addressed current uranium pricing, stressing the need for both spot and long-term prices to rise above $80 to incentivise new development. “Prices have got to go higher. And they have to be built,” he said, referring to new uranium projects. For more videos like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future updates. #GoviExUranium #UraniumMining #MuntangaProject #NuclearEnergy #ZambiaMining #UraniumPrices #EnergySupply #ESIA #UraniumProjects #ProactiveInvestors

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed the company's newly-announced research license agreement with Catalent with Proactive's Stephen Gunnion. Buck shared insights into Lisata’s preclinical evaluation of certepetide using Catalent’s SMARTag antibody-drug conjugate (ADC) platform.. She explained that Catalent would assume all R&D costs, while Lisata provides consulting and stands to receive both upfront and potential milestone payments. Certepetide is described as a unique cyclic non-amino acid peptide, designed to bind to receptors commonly found on solid tumors. Upon binding, it transforms to activate a transport mechanism that boosts therapeutic penetration. "It can work with current therapies and emerging therapies," Buck said, emphasizing its compatibility and favorable safety profile. Buck further discussed the growing relevance of ADCs in oncology. She described ADCs as “biological missiles,” targeting tumors while minimizing harm to healthy tissues. When combined with certepetide, ADCs benefit from deeper tumor penetration and potential immunomodulation, making treatment more effective. The company expects initial data from this collaboration before the end of Q2 2025. Positive results could lead to a deeper relationship with Catalent. Visit Proactive's YouTube channel for more company interviews and updates. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #LisataTherapeutics #KristenBuck #Certepetide #AntibodyDrugConjugates #ADC #OncologyInnovation #CancerResearch #Catalent #BiotechNews #TumorTargeting #ImmunoOncology #SMARTagPlatform

Helix Exploration PLC CEO Bo Sears talked with Proactive's Stephen Gunnion about the company’s development progress at its Rudyard project in Montana. Sears said the company is “progressing nicely” with the Linda #1 well and is on track to begin producing helium by the end of summer. He pointed to strong early results from both Darwin #1 and the acquisition of the Weil #1 well, expressing optimism about long-term production capacity. He described Rudyard as “quite large relative to our peers,” adding that it may support up to 20 wells—substantially more than originally anticipated. This scale opens the potential for on-site helium liquefaction, with HeLIX already acquiring 20 acres in preparation. Sears referenced a 1977 US Bureau of Mines study that estimated the field's potential at 2.60 billion cubic feet of helium. With new drilling data, including from Linda #1 and re-perforated Weil #1, the company expects to significantly update resource estimates. The company anticipates up to 4 billion cubic feet of recoverable helium, which Sears noted could make Helix one of the largest helium producers in the US. Sears also confirmed ongoing discussions with off-takers and potential interest in geological hydrogen from deeper zones. Visit Proactive’s YouTube channel for more interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications for future updates. #HeLIXExploration #HeliumProduction #NaturalGas #RudyardField #BoSears #MontanaEnergy #EnergyExploration #HydrogenExploration #ProactiveInvestors #USHeliumMarket

Optima Health PLC chief executive Jonathan Thomas talked with Proactive's Stephen Gunnion about the company's acquisition of Ireland-based Cognate Health. This deal marks Optima Health’s first foray outside the UK and is aligned with its strategy to supplement organic growth through mergers and acquisitions. Thomas said the move adds around €7 million in revenue and approximately £1 million in EBITDA to the group. Cognate Health is described as a strong platform with 30 clinic facilities across Ireland and around 60 experienced personnel, along with a network of clinicians. According to Thomas, “It’s a really great platform… in addition to obviously the financial aspects… really great opportunities to collaborate, revenue synergies and grow the businesses collectively.” He explained that expanding into a new regulated market provides access to multinational clients seeking services across both the UK and Ireland. The acquisition allows Optima Health to tailor services across jurisdictions while opening up new cross-sell opportunities. Thomas added that the company expects to announce more acquisitions during the year, with several discussions currently underway. Visit Proactive’s YouTube channel for more in-depth business updates and interviews. Don’t forget to give the video a like, subscribe to the channel, and enable notifications so you never miss a story. #OptimaHealth #CognateHealth #HealthcareAcquisition #MergersAndAcquisitions #JonathanThomas #OccupationalHealth #WorkplaceWellbeing #IrelandHealthcare #BusinessExpansion #ProactiveInvestors

SulNOx Group Plc CEO Ben Richardson talked with Proactive's Stephen Gunnion about the company’s financial performance, global expansion and new industry partnerships. Richardson said SulNOx has already exceeded last year’s revenue within the first three quarters of this financial year, with the fourth quarter also showing strong momentum. The company develops patented, all-natural technologies to improve the combustion efficiency of liquid hydrocarbons, reducing both fuel consumption and emissions. During the interview, Richardson highlighted SulNOx’s growing footprint across multiple sectors including marine, logistics, rail, mining and agriculture. “It’s literally every combustion engine on the planet,” he said. The company is targeting global marine fleets, citing that the sector alone accounts for around 5% of worldwide fuel use. SulNOx recently announced a partnership with Colas Rail UK, following successful emissions-reducing trials. The results showed a 5% improvement in fuel efficiency and visible reductions in black smoke emissions from diesel locomotives. Richardson also detailed commercial progress with global shipping giants such as Eastern Pacific Shipping and brokers like McQuilling and Technava. These partners are not only adopting the technology but are also investing in SulNOx and helping introduce it across the industry. With products now sold in over 40 countries and growing interest in biofuel applications, the company is scaling up operations and research. Richardson added, “Growth will happen a lot faster than it has to date. Which is super exciting.” For more updates and interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications so you never miss an update. #SulNOx #CleanTech #FuelEfficiency #EmissionsReduction #GreenShipping #RailFreight #Biofuels #MarineFuels #SustainableEnergy #ProactiveInvestors #BenRichardson #EnergyInnovation

Diales Group PLC (LON:DIAL) CEO Mark Wheeler talked with Proactive's Stephen Gunnion about the company’s global operations and how it supports clients across the engineering and construction sectors—particularly with dispute resolution, cost escalation claims, and complex project planning. Wheeler explained that Diales works with major contractors, joint ventures, government bodies, and clients across infrastructure, energy, and offshore projects. He said, “We support them with their contracts, planning, programming and claims and dispute resolution,” highlighting the company's niche expertise in large-scale, often novel engineering environments. In light of new US tariffs on steel and aluminum, Wheeler said Diales is seeing increased client inquiries and is well-positioned to provide strategic guidance. He noted the company’s experience with “cost escalation claims” and emphasised the value of early contractual advice to manage such risks. He also discussed supply chain challenges, especially where key components are manufactured globally. “One or two small components can really delay the delivery and completion of the construction of some quite significant pieces of equipment,” Wheeler noted. Finally, Wheeler addressed the ongoing share buyback program, which he described as popular with shareholders. He reiterated the company's belief that it is currently “the best value stock to be buying,” particularly given AIM market illiquidity. For more interviews like this one, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe to our channel, and turn on notifications to stay updated on future content. #DialesGroup #EngineeringDisputes #ConstructionSector #GlobalInfrastructure #ShareBuyback #AIMMarket #CostEscalation #SupplyChainIssues #SteelTariffs #MarkWheeler #ConstructionLaw #EnergyProjects #ProactiveInvestors

Ilika PLC CEO Graeme Purdy talked with Proactive's Stephen Gunnion about the company’s latest progress in scaling up its Goliath solid-state battery technology. The discussion focused on improved results from Ilika’s collaboration with the UK Battery Industrialisation Centre (UKBIC). Purdy said: “We’re seeing an improved yield out of the industrialised process,” adding that this reduces waste and lowers costs. More notably, the batteries produced via UKBIC’s process outperform those created on Ilika’s pilot line, showing stronger power density and faster charge-discharge capabilities. Purdy confirmed the project’s shift from process to performance, marking the completion of a £2.7 million grant-supported programme funded by the Advanced Propulsion Centre. He also referenced recent government pledges of £2 billion to back automotive electrification, suggesting that future grant funding could help support Ilika’s product roadmap without shareholder dilution. Looking ahead, Ilika plans to release its P1.5 prototypes—10Ah cells—later this summer. Once enough testing data is gathered, the batteries will be shared with OEMs and Tier 1 suppliers enrolled in its evaluation programme. Purdy also teased the release of 50Ah P2 prototypes by year-end, built on insights gained from the Faraday Battery Challenge. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #IlikaPLC #GoliathBattery #SolidStateBatteries #EVTechnology #BatteryInnovation #UKBIC #AutomotiveElectrification #AdvancedPropulsion #BatteryManufacturing #GraemePurdy

Caledonia Mining Corporation PLC chief executive Mark Learmonth talked with Proactive's Stephen Gunnion about a record first quarter for gold production at the company's Blanket Mine. Learmonth attributed the strong operational performance to significant management changes and the restructuring of the mine's operations, which split underground and surface responsibilities. “We've got a new, younger, more energetic management team underground... and it's worked beautifully,” Learmonth noted, highlighting the benefits of recent personnel shifts and structural reforms. The conversation also covered the recent $22.35 million sale of Caledonia’s solar power plant in Zimbabwe. While the asset has been sold, Learmonth said the company retains a long-term power supply agreement and the option to participate in a second phase, if viable. He clarified the decision allows Caledonia to concentrate more on its core gold mining business. Looking ahead, Learmonth said the company remains focused on maximising gold production while intensifying efforts to reduce long-term costs. “At this gold price, with production strong, we want to get that gold out the ground... with increasing attention now to more management focus on getting those costs down,” he said. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #CaledoniaMining #GoldProduction #BlanketMine #ZimbabweMining #MarkLearmonth #MiningNews #SolarEnergy #EnergyResilience #GoldMining #ProactiveInvestors

Mosman Oil and Gas Ltd CEO Andy Carroll talked with Proactive's Stephen Gunnion about a significant milestone at the company’s Sagebrush-1 well, located in the Leadville formation. Carroll revealed that historic gas sample data from 1993 confirms the presence of helium at a concentration of 2.7%, alongside 20% methane. This discovery enables Mosman to transition from exploration to evaluating the commercialisation of the helium resource. “We were actually looking at a possible work-over at the existing well to get a gas sample, but we've got about 30 boxes of data from the previous operator and found in those boxes the original gas sample report,” Carroll said. The gas flow rate from the earlier test was in the range of 152 to 163 thousand cubic feet per day, indicating potential for commercial development. Carroll also noted the strategic benefit of methane being present alongside the helium. The methane could be used for on-site power generation to support helium processing, reducing dependence on external power sources. Additionally, existing infrastructure—including a mothballed pipeline and nearby helium plants—could significantly streamline transportation and processing. Looking ahead, Mosman is preparing feasibility studies and engaging with the Ute Mountain Ute Tribe and regulatory authorities to conduct further 3D seismic work. These efforts aim to refine drilling plans across the Sagebrush area and adjacent Coyote Wash leases. Visit Proactive's YouTube channel for more insightful updates, and don't forget to like this video, subscribe to our channel, and turn on notifications so you don’t miss future content. #MosmanOilAndGas #HeliumDiscovery #SagebrushOne #LeadvilleFormation #EnergyStocks #NaturalGas #MethanePower #HeliumCommercialisation #OilAndGasExploration #ProactiveInvestors

Solvonis Therapeutics PLC CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's transformation and its strategy moving into 2025. Tennyson explained that the company, formerly known as Graft Polymer, exited its industrial plastics business in 2024 to focus entirely on biotechnology, particularly mental health and addiction treatments. "These are segments which have large addressable markets, poor current standards of care and therefore significant unmet medical needs," he said. He outlined how the company raised £1.8 million in mid-2024 to support its new growth strategy, which includes partnerships, joint ventures, and acquisitions. A central part of this strategy is the pending acquisition of Awakn Life Sciences, a clinical-stage biotech company focused on alcohol use disorder (AUD) and PTSD. Solvonis is acquiring Awakn in an all-paper deal valued between £3 million and £5 million. Tennyson said this represented significant value, highlighting that similar assets could command substantially higher valuations. Awakn’s AWKN-001, targeting severe AUD, is in phase 3 trials in the UK and EU. AWKN-002, for the US market, has received FDA support for a faster 505(b)(2) development pathway, allowing the use of Johnson & Johnson’s SPRAVATO® data to accelerate progress. Tennyson said the top priority for 2025 is closing and integrating the acquisition and executing on the clinical programs. He emphasised plans to file for FDA approval of a phase 2B trial and to continue to work with Awakn's existing UK partners. Visit Proactive's YouTube channel for more updates like this. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #Solvonis #BiotechNews #MentalHealthTreatment #AddictionRecovery #PTSDResearch #AlcoholUseDisorder #PharmaInvesting #AwaknAcquisition #ClinicalTrials #HealthcareInnovation